On February 9, 2023 Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, reported that it will present findings from its drug discovery and development programs at the 46th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), being held in Orlando, Florida February 11–15, 2023 (Press release, Decibel Therapeutics, FEB 9, 2023, View Source [SID1234626989]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Company will present new data on its lead investigational gene therapy product candidate, DB-OTO, as well as new data across its gene therapy pipeline. Decibel will also present additional data from the interim analysis of the Phase 1b clinical trial of DB-020 in patients receiving cisplatin chemotherapy.
Podium Presentations
Podium 1 | Precise Targeting of GJB2 Cells Results in Safe and Efficacious Gene Therapy in a Rodent Model of Hearing Loss Due to GJB2 Deficiency
Presenter: Kathryn Ellis, Ph.D.
Session Title: Gene Therapy
Date & Time: Saturday, February 11, 2:00 – 4:00 p.m. ET
Podium 26 | Development of DB-020, a Locally Administered Product for Protection Against Cisplatin-Induced Ototoxicity
Presenter: John Lee
Session Title: Cisplatin Ototoxicity
Date & Time: Tuesday, February 14, 10:30 a.m. – 12:30 p.m. ET
Poster Presentations
SU83 | Development of a Platform for Parallel Functional Evaluation of Cell Type Specific Synthetic Promoters for Gene Therapy
SU84 | Dual Vector Gene Therapy Approaches for STRC-Related Hearing Loss
MO83 | Nonclinical Pharmacology, Biodistribution, and Safety Studies Supporting the Clinical Development of DB-OTO (AAV1-Myo15-hOTOFv5) for Hearing Loss Due to Genetic Otoferlin Protein Deficiency
TU83 | Development of a Utricle Culture System for Exploring Dual AAV-Mediated Expression Kinetics of Human Otoferlin
TU232 | Advancing Bioinformatically Informed Targets to Achieve In Vivo Vestibular Regeneration